NCCN Releases New Guidelines for Pediatric Soft Tissue Sarcomas
The National Comprehensive Cancer Network (NCCN) has recently published new clinical practice guidelines for pediatric soft tissue sarcoma care 1. These guidelines specifically focus on rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in patients under 20 years of age 1, 3.
Understanding Rhabdomyosarcoma
RMS represents nearly 5% of all childhood cancers 3. The guidelines aim to balance effective treatment with minimizing adverse effects, recognizing that childhood cancers differ fundamentally from those in adults 3.
Treatment Approaches
Treatment for RMS typically involves a combination of chemotherapy, surgery, and radiation therapy, tailored to the patient’s risk group, age, and developmental stage.
Key Considerations in the Guidelines
The NCCN guidelines provide a roadmap for diagnosing, risk stratifying, and treating patients with pediatric soft tissue sarcomas. They offer site-specific considerations, including:
- Head or neck mass
- Soft tissue mass of the extremity
- Soft tissue mass of the trunk
- Mass of the vulva, vagina, uterus fundus/cervix
- Paratesticular mass
- Bladder or prostate mass
- Biliary/liver mass
Risk Stratification
The guidelines outline criteria for classifying patients into very-low-risk, low-risk, intermediate-risk, and high-risk categories, with corresponding treatment options for each.
Surveillance Recommendations
For patients with no active disease, the guidelines recommend a surveillance schedule including:
- History and physical examination every 3 to 6 months for 2 to 3 years, then every 6 to 12 months for years 4 and 5, then annually
- Imaging (primary site and chest CT or chest x-ray) every 3 to 6 months for 2 to 3 years, every 6 to 12 months for years 4 and 5, then annually
- Whole body fluorodeoxyglucose-PET imaging as clinically indicated
Systemic Therapy Regimens
Vincristine and dactinomycin are commonly used in treatment regimens across all risk levels, sometimes combined with cyclophosphamide and maintenance therapy.
Potential Treatment Risks
The guidelines also address potential risks associated with treatment, including:
- Vasospastic attacks with chemotherapy
- Risks associated with radiotherapy (subsequent benign or malignant neoplasm, pulmonary toxicity, cardiac toxicity, functional asplenia, renal toxicity)
- Risks associated with surgery (amputation-related complications, cystectomy-related complications, bowel obstruction, urinary incontinence, asplenia, pulmonary dysfunction, hypothyroidism)
Expert Perspective
According to Stephen Skapek, MD, Chair of the NCCN Guidelines Panel for Pediatric Soft Tissue Sarcoma, “RMS can be divided into specific subtypes that are driven by different genetic changes that can influence outcomes. Those changes and other clinical and pathology features are all incorporated into the multi-faceted treatments.” 3
Douglas Hawkins, MD, added, “Children are most likely to be diagnosed with RMS at a very young age… When treating someone so young, you are not looking to just prolong survival; the goal is a full cure with minimal [adverse] effects and zero recurrence.” 3
Accessing the Guidelines
The new NCCN Guidelines for Pediatric Soft Tissue Sarcomas are available for free at NCCN.org.
The post NCCN Guidelines for Pediatric Rhabdomyosarcoma (RMS) Care appeared first on Archynewsy.